GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » 6-Month Share Buyback Ratio

Imugene (ASX:IMU) 6-Month Share Buyback Ratio : -1.63% (As of Dec. 2024 )


View and export this data going back to 1993. Start your Free Trial

What is Imugene 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Imugene's current 6-Month Share Buyback Ratio was -1.63%.

Competitive Comparison of Imugene's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, Imugene's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imugene's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Imugene's 6-Month Share Buyback Ratio falls into.


;
;

Imugene 6-Month Share Buyback Ratio Calculation

Imugene's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2024 ) - Shares Outstanding (EOP) (Dec. 2024 )) / Shares Outstanding (EOP) (Jun. 2024 )
=(7320.355 - 7439.400) / 7320.355
=-1.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene  (ASX:IMU) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Imugene 6-Month Share Buyback Ratio Related Terms

Imugene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » 6-Month Share Buyback Ratio
Comparable Companies
ASX:DXB ASX:RAC ASX:PAR ASX:OCC ASX:ACW ASX:AGN ASX:ALA ASX:LTP ASX:IMM ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IUGNF:USA ILA:Germany
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines